Peptide Inhibitors for Selective p53 Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer and stress-related conditions often cause adverse side effects due to excessive activation of the p53 protein, leading to damage in normal tissues and limiting the effectiveness of therapies, as existing methods struggle to selectively inhibit p53 activity in normal cells during cancer treatment.
Innovation Solution
Development of peptides recognized by monoclonal anti-DNA antibodies that exhibit anti-apoptotic and anti-inflammatory properties, capable of inhibiting cellular and immune stress responses, thereby reducing cell death and inflammation in normal tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If p53 activity is activated to eliminate damaged cells, then tumor suppression is improved, but normal tissue damage increases
Solution Approach 1:
The patent applies local quality by creating peptides with specific sequences that selectively interact with p53 in damaged cells versus normal cells. The peptides are designed to recognize specific epitopes on p53 that are exposed or modified in stressed/damaged cells, allowing localized inhibition of p53-mediated apoptosis in normal tissues while preserving its tumor-suppressing function in aberrant cells.
Solution Approach 2:
The patent employs parameter changes by modifying peptide sequences to alter their binding affinity and specificity for p53. By changing amino acid compositions and structures of the peptides, they achieve differential effects on p53 activity in different cell types, reducing normal tissue damage while maintaining anti-tumor efficacy.
2Productivity
If chemotherapy and radiation therapy are used to treat cancer, then tumor cell death is improved, but side effects in normal tissues increase
Solution Approach 1:
The patent introduces peptides as intermediary molecules that mediate between chemotherapy/radiation therapy and p53 signaling pathways. These peptides act as protective agents that specifically intercept p53 activation in normal cells exposed to treatment, preventing excessive apoptosis and reducing side effects without interfering with the therapeutic killing of tumor cells.
Solution Approach 2:
The patent applies preliminary anti-action by administering p53-inhibiting peptides before or during chemotherapy/radiation treatment to pre-protect normal cells from p53-mediated damage. This preemptive approach allows normal tissues to withstand the stress of treatment while maintaining the ability to eliminate tumor cells.
3Stability of the object's composition
If p53 is continuously activated to prevent tumor formation, then genomic stability is improved, but cell death in normal tissues increases
Solution Approach 1:
The patent applies dynamics by creating a dynamic balance between p53 activation and inhibition. The peptides provide reversible, condition-dependent modulation of p53 activity, allowing the system to adapt: p53 remains active in tumor-prone cells to maintain genomic stability, while being inhibited in normal cells to preserve cell survival during stress responses.
Data Source
AI summary
The present invention relates to peptides capable of inhibiting cellular and immune stress responses in a eukaryotic cell. The invention provides compositions and methods for the treatment of human degenerative diseases and inflammation, utilizing these peptides.